Euroespes, S.A (EEP) Fair Value & Analysis
Healthcare · ES · Market cap €3.9M
Fair value as of: Jul 24, 2026
From 13 valuation models · updated 17 days ago
Share price −37.0% over the past month.
A solid business, but screening 18% overvalued on our models.
What matters now
- The model range is unusually wide (€0.1400 to €0.4300). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range €0.3400 – €0.5800 · fair‑value band €0.1400 – €0.4300 · the €0.3400 price screens above the €0.2800 fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Euroespes, S.A (EEP) currently trades at €0.3400, while our model-based Fair Value estimate is €0.2800, implying the stock looks roughly 17.7% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Euroespes, S.A generated revenue of €3.9M at a net margin of -29.5%. Revenue declined 16.8% year over year. It earns a return on equity of -16.7%. Net debt stands at €2.6M. Fundamentals as of Jul 24, 2026
Our scenario range runs from €0.1400 (bear case) to €0.4300 (bull case); at €0.3400, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 37% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -48% fair-value upside, at -18%, EEP screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: Multiples (€0.7100) versus Growth DCF (€0.0800). Highest evidence: Growth DCF (80).
Notify me when EEP reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes.
Full company description
Euroespes, S.A., a medical center, provides medical services for the research, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. It offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. The company also provides medical services, such as neuro-ophthalmology, neuro-otorhinolaryngology, neuropsychology, digital diagnostics, radiodiagnosis, clinical analysis laboratory, nursing, and cardiology. In addition, it researches and develops in the fields of biochemistry, health biotechnology, epigenetics, pharmacogenomics, and nutraceuticals. The company was founded in 1991 and is based in Corunna, Spain.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Euroespes, S.A reported revenue of €2.9M in FY2025 versus €3.3M in FY2021, a compound −3.3%/yr. Reported net income was €923 in FY2025.
EEP screens 18% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 135 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $543.19 | $308.19 | -43% |
| Danaher Corporation DHR | $199.66 | $103.88 | -48% |
| WuXi AppTec Co 2359 | HK$160.70 | HK$125.20 | -22% |
| Lonza Group LONN | CHF 567.80 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $567.44 | $255.77 | -55% |
| Agilent Technologies, Inc A | $131.46 | $62.70 | -52% |
| Waters Corporation WAT | $368.98 | $121.96 | -67% |
| IQVIA Holdings IQV | $207.85 | $134.18 | -35% |
| Integrated Diagnostics Holdings IDHC | $0.0050 | $0.0053 | +5% |
| Illumina, Inc ILMN | $186.65 | $95.51 | -49% |
Compare Euroespes, S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Euroespes, S.A (EEP) overvalued or undervalued?
What is the fair value of EEP?
What is the quality score of EEP?
What is the revenue of Euroespes, S.A (EEP)?
What is the net profit margin of EEP?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Euroespes, S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.